259 related articles for article (PubMed ID: 29023527)
1. Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients.
Zschaeck S; Blümke B; Wust P; Kaul D; Bahra M; Riess H; Klein F; Sinn M; Pelzer U; Budach V; Ghadjar P
PLoS One; 2017; 12(10):e0186341. PubMed ID: 29023527
[TBL] [Abstract][Full Text] [Related]
2. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation.
Krishnan S; Chadha AS; Suh Y; Chen HC; Rao A; Das P; Minsky BD; Mahmood U; Delclos ME; Sawakuchi GO; Beddar S; Katz MH; Fleming JB; Javle MM; Varadhachary GR; Wolff RA; Crane CH
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):755-65. PubMed ID: 26972648
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study.
Passoni P; Reni M; Cattaneo GM; Slim N; Cereda S; Balzano G; Castoldi R; Longobardi B; Bettinardi V; Gianolli L; Gusmini S; Staudacher C; Calandrino R; Di Muzio N
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1000-6. PubMed ID: 24267968
[TBL] [Abstract][Full Text] [Related]
4. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT.
Gkika E; Adebahr S; Kirste S; Schimek-Jasch T; Wiehle R; Claus R; Wittel U; Nestle U; Baltas D; Grosu AL; Brunner TB
Strahlenther Onkol; 2017 Jun; 193(6):433-443. PubMed ID: 28138949
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
7. Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer.
Cihoric N; Tsikkinis A; Tapia C; Aebersold DM; Zlobec I; Lössl K
Radiat Oncol; 2015 Nov; 10():240. PubMed ID: 26597282
[TBL] [Abstract][Full Text] [Related]
8. The technical feasibility of an image-guided intensity-modulated radiotherapy (IG-IMRT) to perform a hypofractionated schedule in terms of toxicity and local control for patients with locally advanced or recurrent pancreatic cancer.
Son SH; Song JH; Choi BO; Kang YN; Lee MA; Kang KM; Jang HS
Radiat Oncol; 2012 Dec; 7():203. PubMed ID: 23216796
[TBL] [Abstract][Full Text] [Related]
9. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer.
Chadha AS; Skinner HD; Gunther JR; Munsell MF; Das P; Minsky BD; Delclos ME; Chatterjee D; Wang H; Clemons M; George G; Singh PK; Katz MH; Fleming JB; Javle MM; Wolff RA; Varadhachary GR; Crane CH; Krishnan S
PLoS One; 2016; 11(6):e0156910. PubMed ID: 27336466
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
[TBL] [Abstract][Full Text] [Related]
11. Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysis.
Wang Z; Ren ZG; Ma NY; Zhao JD; Zhang Z; Ma XJ; Long J; Xu J; Jiang GL
Radiat Oncol; 2015 Jan; 10():14. PubMed ID: 25575617
[TBL] [Abstract][Full Text] [Related]
12. Accelerated hyperfractionated intensity-modulated radiotherapy for recurrent/unresectable rectal cancer in patients with previous pelvic irradiation: results of a phase II study.
Cai G; Zhu J; Hu W; Zhang Z
Radiat Oncol; 2014 Dec; 9():278. PubMed ID: 25497847
[TBL] [Abstract][Full Text] [Related]
13. Helical tomotherapy with simultaneous integrated boost after laparoscopic staging in patients with cervical cancer: analysis of feasibility and early toxicity.
Marnitz S; Köhler C; Burova E; Wlodarczyk W; Jahn U; Grün A; Budach V; Stromberger C
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e137-43. PubMed ID: 21600704
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
15. Intensity-modulated and image-guided radiotherapy in patients with locally advanced inoperable pancreatic cancer after preradiation chemotherapy.
Sinn M; Ganeshan R; Graf R; Pelzer U; Stieler JM; Striefler JK; Bahra M; Wust P; Riess H
ScientificWorldJournal; 2014; 2014():452089. PubMed ID: 25401140
[TBL] [Abstract][Full Text] [Related]
16. Methods, safety, and early clinical outcomes of dose escalation using simultaneous integrated and sequential boosts in patients with locally advanced gynecologic malignancies.
Boyle J; Craciunescu O; Steffey B; Cai J; Chino J
Gynecol Oncol; 2014 Nov; 135(2):239-43. PubMed ID: 25192879
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients.
Mattiucci GC; Boldrini L; Nardangeli A; D'Aviero A; Buwenge M; Cellini F; Deodato F; Dinapoli N; Frascino V; Macchia G; Morganti AG; Valentini V
J Cancer Res Clin Oncol; 2021 Mar; 147(3):661-667. PubMed ID: 33001271
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and toxicity of helical tomotherapy for patients with locally recurrent nasopharyngeal carcinoma.
Puebla F; Lopez Guerra JL; Garcia Ramirez JM; Matute R; Marrone I; Miguez C; Sevillano D; Sanchez-Reyes A; Rivin Del Campo E; Praena-Fernandez JM; Azinovic I
Clin Transl Oncol; 2015 Nov; 17(11):925-31. PubMed ID: 26108408
[TBL] [Abstract][Full Text] [Related]
19. 5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: Phase I-II dose-escalation study.
Morganti AG; Valentini V; Macchia G; Mattiucci GC; Costamagna G; Deodato F; Smaniotto D; Luzi S; Balducci M; Barbi S; Perri V; Trodella L; Cellini N
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1454-60. PubMed ID: 15275732
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of preoperative helical tomotherapy with a simultaneous integrated boost for rectal cancer.
Engels B; Tournel K; Everaert H; Hoorens A; Sermeus A; Christian N; Storme G; Verellen D; De Ridder M
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):142-8. PubMed ID: 22014952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
